PDL BioPharma, Inc. (PDLI) Cash Flow Statement

Click line-items for a historical chart and %

Cash flows from operating activities
Net income	53.47M
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of convertible notes offering costs	3.25M
Amortization of non-recourse notes offering costs
Other amortization and depreciation expense
Loss on retirement or conversion of convertible notes
Stock-based compensation expense
Tax (expense) benefit from stock-based compensation arrangements
Net excess tax benefit from stock-based compensation
Deferred income taxes
Changes in assets and liabilities:
Receivables from licensees	216K
Prepaid and other current assets	-438K
Other assets	1.15M
Accounts payable
Accrued liabilities	-669K
Accrued legal settlement	0
Accrued income taxes
Other long-term liabilities
Deferred revenue
Net cash provided by operating activities	54M
Cash flows from investing activities
Purchases of investments
Maturities of investments
Purchase of intangible assets
Net cash used in investing activities	17.96M
Cash flows from financing activities
Repurchase of convertible notes
Repayment of non-recourse notes
Cash dividend paid	-20.98M
Net proceeds from the issuance of convertible notes
Purchase of call options
Proceeds from issue of warrants
Net excess tax benefit from stock-based compensation
Net cash used in financing activities	-20.98M
Net decrease in cash and cash equivalents	50.98M
Cash and cash equivalents at beginning of the period	131.21M
Cash and cash equivalents at end of the period	182.19M

Entities mentioned with PDLI

View All Entities